Navigation Links
Landmark studies assess risk of exposure to elevated levels of EMS confirm clear toxicity threshold
Date:8/4/2008

Basel, 4 August 2008. New data from studies presented at the XVII International AIDS Conference in Mexico City have provided unprecedented insight into the toxicity of an impurity called ethyl methanesulfonate (EMS). The formation of the EMS impurity is a potential by-product of the manufacturing of mesylate salts, which are contained in over 40 drugs currently available worldwide.

The studies were designed to determine the impact of elevated EMS levels in some batches of Roche's Viracept (nelfinavir mesylate) and demonstrated a clear threshold response at which DNA damage, the underlying mechanism for the carcinogenesis of EMS, occurs. The results of these animal studies, which can be translated to humans with high confidence, confirm that Viracept patients exposed to the EMS impurity at levels well below this threshold are not at an increased risk of cancer.

"These data provide unprecedented insight into the toxicity of EMS for humans. They will change the long held perceptions of the hazards posed by low doses of some genotoxic carcinogens", said Professor David Tweats, Department of Medicine and Genetics, University of Wales Swansea, UK.

EMS is a known DNA-damaging agent capable of inducing gene mutations and chromosomal aberrations. Although existing in vitro data indicated that there was a threshold response at lower doses of EMSi at which no DNA damage was observed, the total body of literature about EMS at low doses was limited. Consequently, available data did not permit an adequate risk assessment for patients exposed to EMS in Viracept. Roche -- in agreement with the European regulatory agency -- undertook the largest and most comprehensive toxicology evaluation of EMS to-date.

Scientists investigated the genetic toxicity of EMS using the following sets of studies:

  • Measurement of chromosomal damage in mice

  • Quantification of gene mutations in the transgenic MutaMouse model - the largest study of its kind ever conducted

  • Modelling of exposure and metabolism of EMS in humans based on experimental animal data

The first study clearly demonstrated a threshold-dose response with no chromosomal damage at EMS doses up to and including, 80 mg/kg/day. The second set of studies, the transgenic MutaMouse studies, also showed a clear threshold effect for mutations above 25 mg/kg/day, under chronic conditions. Effects were also shown not to be cumulative over time. This threshold is far above 0.055 mg/kg/day -- the highest estimated levels to which Viracept patients were exposed for no longer than 3-6 months.

The research team used these results to predict human exposure to EMS. They predicted that even at a maximal exposure level 370-fold higher than that calculated for affected Viracept patients, the damage potentially incurred by EMS can still effectively be dealt with by ubiquitous DNA repair mechanisms. As chromosome damage and mutations are the underlying molecular events for birth defects and cancer, the results of these studies can be used to reassure patients exposed to elevated levels of EMS, and their healthcare providers, that they are not at increased risk for developing cancer.


'/>"/>

Contact: Sbastien Desprez
sebastien.desprez@ketchum.com
44-077-682-38289
Ketchum
Source:Eurekalert

Related biology news :

1. Safeway Inc. and PCF to fund landmark prostate cancer research collaboration
2. SAGE and Hindawi announce landmark open access agreement
3. Claims of sex-related differences in genetic association studies often not properly validated
4. Genes, Environment and Health Initiative invests in genetic studies, environmental monitoring
5. NIH awards researcher $1.5 million new innovator grant for fruit-fly studies of prion proteins
6. Studies: Children obese due to a host of unhealthy pressures
7. Clinical studies show REMICADE reduces incidence of bowel surgeries in ulcerative colitis patients
8. LSU professor studies army-ant-following birds
9. 2 carotid artery stenting studies show results comparable to AHA guidelines
10. NIH grants enable energy studies
11. New studies on schizophrenia, depression, trauma and autism highlight annual meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/25/2016)... , Jan. 25, 2016  Glencoe Software, the ... pharma and publication industries, will provide the data management ... Centre (NPSC). ... Phenotypic analysis measures ... whole organisms, allowing comparisons between states such as health ...
(Date:1/21/2016)... 21, 2016 --> ... market research report "Emotion Detection and Recognition Market by Technology ... (Facial Expression, Voice Recognition and Others), Services, Application ... to 2020", published by MarketsandMarkets, the global Emotion ... USD 22.65 Billion by 2020, at a CAGR ...
(Date:1/20/2016)... 20, 2016  Synaptics Incorporated (NASDAQ: SYNA ... today announced sampling of S1423, its newest ClearPad ... small screen applications including smartwatches, fitness trackers, and ... and rectangular shapes, as well as thick and ... moisture on screen, while wearing gloves, and supports ...
Breaking Biology News(10 mins):
(Date:2/10/2016)... ... February 10, 2016 , ... SonaCare Medical, LLC reports the ... Sonalink™ remote monitoring. The inaugural launch of this new technology occurred over the ... Samuel Peretsman to a HIFU technical expert at SonaCare Medical headquarters. , ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... now available on Microsoft Azure. On Azure, Arvados provides capabilities for managing and ... clear demand for Microsoft Azure from major institutions collecting and analyzing genomic data,” ...
(Date:2/10/2016)... ... ... Cenna Bioscience Inc., an emerging biopharmaceutical company focused on the discovery and ... been selected to present at the Cavendish Global Health Impact Forum taking place February ... of the Forum is to help family offices and foundations develop and implement their ...
(Date:2/9/2016)... ... ... With a presidential election in November and the future of U.S. healthcare in ... top healthcare leaders for a night and day of debates and discussions about what ... the University of Pennsylvania’s Wharton School, will be held February 18 – 19, 2016 ...
Breaking Biology Technology: